JMP Securities raised the firm’s price target on HealthEquity (HQY) to $120 from $107 and keeps an Outperform rating on the shares amid a broader research note on Healthcare Services. The firm views a higher multiple as warranted given interest rate resiliency and the company’s strong sales momentum to finish fiscal 2025, the analyst says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity Projects Record Growth for Fiscal Year 2025
- HealthEquity announces year-end HSA sales outlook
- Leadership Change at Healthequity Inc.: Challenges and Risks as Scott Cutler Steps In as CEO
- HealthEquity price target lowered to $112 from $120 at Barrington
- HealthEquity price target raised to $105 from $100 at RBC Capital